ブクラデシン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/12/19 09:39:49」(JST)
[Wiki en表示]
Bucladesine
|
| Clinical data |
| Synonyms |
• Dibutyryl cyclic adenosine monophosphate
• (N6,2'-O-dibutyryl)-adenosine-3',5'-mono-phosphate
• Dibutyryl cAMP
• DcAMP
• DBcAMP |
| AHFS/Drugs.com |
International Drug Names |
| ATC code |
|
| Identifiers |
IUPAC name
- boring(3aR,4R,6R,6aR)-4-(6-butanamido-9H-purin-9-yl)-6-[(butanoyloxy)methyl]-2-oxo-tetrahydro-2H-1,3,5,2λ5-furo[3,4-d][1,3,2]dioxaphosphol-2-olate
|
| CAS Number |
|
| PubChem CID |
|
| IUPHAR/BPS |
|
| ChemSpider |
|
| UNII |
|
| ChEBI |
|
| ChEMBL |
|
| ECHA InfoCard |
100.006.046 |
| Chemical and physical data |
| Formula |
C18H23N5NaO8P |
| Molar mass |
491.368 g/mol |
| 3D model (JSmol) |
|
SMILES
-
O=C(Nc4ncnc1c4ncn1[C@@H]2O[C@@H]3COP(=O)(O[C@H]3[C@H]2OC(=O)CCC)O)CCC
|
InChI
-
InChI=1S/C18H24N5O8P/c1-3-5-11(24)22-16-13-17(20-8-19-16)23(9-21-13)18-15(30-12(25)6-4-2)14-10(29-18)7-28-32(26,27)31-14/h8-10,14-15,18H,3-7H2,1-2H3,(H,26,27)(H,19,20,22,24)/t10-,14-,15-,18-/m1/s1 Y
-
Key:CJGYSWNGNKCJSB-YVLZZHOMSA-N Y
|
| (verify) |
Bucladesine is a cyclic nucleotide derivative which mimics the action of endogenous cAMP and is a phosphodiesterase inhibitor.
Bucladesine is a cell permeable cAMP analog. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions. cAMP is only able to elicit minimal responses in these situations.
The neurite outgrowth instigated by bucladesine in cell cultures has been shown to be enhanced by nardosinone.
Contents
- 1 Bucladesine and seizure
- 2 Bucladesine and morphine withdrawal syndrome
- 3 References
- 4 External links
Bucladesine and seizure
Recently, the effect of bucladesine as a cAMP analog has been studied on the pentylenetetrazol-induced seizure in the wild-type mice. The data showed that bucladesine (300nM/mouse) reduced the seizure latency and threshold. In addition they found that combination of bucladesine and pentoxyfillin has additive effect on seizure latency and threshold.[1]
Bucladesine and morphine withdrawal syndrome
Bucladesine (50-100nM/mouse) showed significant attenuation in the morphine withdrawal syndrome in the wild-type mice. In addition, its high dose (200nM/mouse) combination with H-89, as a protein kinase inhibitor, had additive attenuating effect on withdrawal syndromes.[2]
References
- ^ Hosseini-Zare MS, Salehi F, Seyedi SY, Azami K, Ghadiri T, Mobasseri M, Gholizadeh S, Beyer C, Sharifzadeh M (2011). "Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice". European Journal of Pharmacology. 670 (2–3): 464–70. doi:10.1016/j.ejphar.2011.09.026. PMID 21946102.
- ^ Seyedi SY, Salehi F, Payandemehr B, Hossein S, Hosseini-Zare MS, Nassireslami E, Yazdi BB, Sharifzadeh M (2014). "Dual effect of cAMP agonist on ameliorative function of PKA inhibitor in morphine-dependent mice". Fundamental & Clinical Pharmacology. 28 (4): 445–54. doi:10.1111/fcp.12045. PMID 24033391.
External links
- Bucladesine at the US National Library of Medicine Medical Subject Headings (MeSH)
|
Cardiac stimulants excluding cardiac glycosides (C01C)
|
Adrenergic and
dopaminergic agents |
| Adrenergic agonists |
| α |
- Metaraminol
- Phenylephrine
- Methoxamine
- Norfenefrine
- Oxedrine
- Midodrine
- Mephentermine
|
| β |
- Dobutamine
- Arbutamine
- Isoprenaline
- Prenalterol
|
| mixed |
- Amezinium metilsulfate
- Droxidopa
- Epinephrine #
- Norepinephrine
- Etilefrine
|
|
| Dopamine agonists |
|
| Both |
- Dopamine #
- Dopexamine
- Ibopamine
- octopamine
|
| Unknown/ungrouped |
- Dimetofrine
- Gepefrine
- Cafedrine
- Theodrenaline
|
|
| Phosphodiesterase inhibitors (PDE3I) |
- Amrinone
- Milrinone
- Enoximone
- Bucladesine
|
| Other cardiac stimulants |
- Angiotensinamide
- Xamoterol
- Levosimendan
- Pimobendan
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
English Journal
- Insulin receptor substrates form high-molecular-mass complexes that modulate their availability to insulin/insulin-like growth factor-I receptor tyrosine kinases.
- Fukushima T, Arai T, Ariga-Nedachi M, Okajima H, Ooi Y, Iijima Y, Sone M, Cho Y, Ando Y, Kasahara K, Ozoe A, Yoshihara H, Chida K, Okada S, Kopchick JJ, Asano T, Hakuno F, Takahashi S.SourceDepartment of Animal Sciences, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan.
- Biochemical and biophysical research communications.2011 Jan 21;404(3):767-73. Epub 2010 Dec 17.
- Insulin receptor substrates (IRSs) are phosphorylated by activated insulin/insulin-like growth factor (IGF)-I receptor tyrosine kinases. Phosphotyrosyl IRSs are recognized by signaling molecules possessing src homology region 2 (SH2) domains, which mediate various insulin/IGF bioactivities. However,
- PMID 21168390
- Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP.
- Arnold DE, Gagne C, Niknejad N, McBurney MW, Dimitroulakos J.SourceCentre for Cancer Therapeutics, The Ottawa Hospital Research Institute, Ottawa Regional Cancer Centre, 503 Smyth Road, Third Floor, Ottawa, ON, K1H 1C4, Canada.
- Molecular and cellular biochemistry.2010 Dec;345(1-2):1-11. Epub 2010 Aug 9.
- Differentiation-based therapeutics are an underutilized but a potentially significant treatment option for cancer patients. We show that lovastatin, a competitive inhibitor of the rate-limiting enzyme of mevalonate synthesis HMG-CoA reductase, is able to induce tumour cell differentiation and apopto
- PMID 20694854
Japanese Journal
- ブクラデシンナトリウム軟膏と白糖・ポビドンヨード配合剤の混合比率による創傷治癒および殺菌効果の検討
- 武川 力,橋本 裕之,佐藤 精一
- 日形会誌 : 日本形成外科学会会誌 = Journal of Japan Society of Plastic and Reconstructive Surgery 31(8), 513-520, 2011-08-20
- NAID 10029531483
- Involvement of K^+ Channels and Na^+, K^+-ATPase in Relaxant Actions of Selective Phosphodiesterase 3 Inhibitors on Airway and Vascular Smooth Muscles Isolated from Guinea-pigs
- Tsurumi Tomoko,Uchida Kohsuke
- Dokkyo journal of medical sciences 34(1), 7-20, 2007-03
- … Similar observations were seen on the bucladesine (a cyclic AMP mimic agent)-induced relaxation. …
- NAID 110006966435
- 扇 和弘,成田 憲彦,意元 義政 [他],伊藤 有未,都築 秀明,山田 武千代,藤枝 重治
- 耳鼻咽喉科臨床 99(4), 295-298, 2006-04-01
- … Bucladesine sodium, that is used for pressure ulcers, was administrated for the treatment. …
- NAID 10017546282
Related Links
- Bucladesineとは？goo Wikipedia (ウィキペディア) 。出典：Wikipedia（ウィキペディア）フリー百科事典。 Bucladesineとは - goo Wikipedia (ウィキペディア) gooトップ サイトマップ スタートページに設定 RSS ヘルプ メニューへスキップ ...
- Bucladesine Sodium 販売元 和光純薬工業(株) 販売元コード 023-16381,029-16383 製造元 製造元コード CAS.NO 16980-89-5 分子式 C18H23N5NaO8P 分子量 491.37 保存条件 冷蔵 (氷冷輸送) 適用法規 危険有害性 等級 薬理研究 ...
★リンクテーブル★
[★]
- 英
- bucladesine、
- 同
- ジブチリル環状AMP, ジブチリルcAMP, db-cAMP, dbcAMP, dibutyryl cyclic AMP
- 化
- ブクラデシンナトリウム bucladesine sodium
- 商
- アクトシン
- 関
- 強心剤
[★]
- 英
- dibutyryl cyclic AMP、bucladesine、db-cAMP、dbcAMP
- 関
- ブクラデシン、ジブチリルサイクリックAMP
[★]
- 関
- bucladesine、dbcAMP、dibutyryl cyclic AMP
[★]
ジブチリルサイクリックAMP、ジブチリル環状AMP
- 関
- bucladesine、db-cAMP、dbcAMP
[★]
- 関
- bucladesine、db-cAMP、dibutyryl cyclic AMP
[★]
ブクラデシン bucladesine。ブクラデシンナトリウム